Telomir Pharmaceuticals, Inc. reported on November 24, 2025, that its product Telomir-1 significantly reduces PSA levels in prostate cancer cells, indicating potential effectiveness in treatment. The research showed effective tumor reduction in preclinical studies, suggesting promising advancements in cancer therapy.